Is tigecycline's liver safety affected by hepatic impairment?

What does hepatic impairment do to tigecycline exposure?

Tigecycline dosing and exposure change in people with hepatic impairment. The prescribing information indicates that hepatic impairment increases tigecycline exposure, which means liver dysfunction can affect how much drug the body sees during treatment [1].

Is tigecycline considered unsafe in liver disease, or is it just higher exposure?

The key issue is higher tigecycline exposure rather than a specific liver-toxicity warning that hepatic impairment directly worsens the safety risk. The available guidance is that impaired liver function leads to higher exposure, so clinicians account for this when deciding on use [1].

Does it change the recommended dose?

For tigecycline, the labeling guidance focuses on how hepatic impairment affects exposure rather than a simple “use a lower dose in everyone with liver impairment.” Instead, the product information provides hepatic-impairment handling consistent with the increased exposure seen in such patients [1].

What liver safety concerns should patients and clinicians watch for?

Because hepatic impairment increases tigecycline exposure, clinicians typically monitor liver-related lab values and signs of liver injury during therapy, especially in patients who already have liver disease [1].

Source

1. DrugPatentWatch.com – Tigecycline (Tygacil) label/overview references